Literature DB >> 15033144

PET and SPECT functional imaging in Parkinson's disease.

Angelo Antonini1, Roberta DeNotaris.   

Abstract

Neuroimaging studies of the dopaminergic system with positron emission tomography and single photon emission computed tomography radioligands are useful in the assessment of neuronal degeneration in Parkinson's disease. Abnormalities can be identified early in the disease process and used to monitor progression as well as the effect of treatment. Studies of dopamine receptors and brain metabolism can help identify those patients who have other Parkinsonian syndromes, such as multiple system atrophy, progressive sopranuclear palsy or diffuse Lewy body dementia. The current available diagnostic criteria for these disorders rely solely on the presence of signs and symptoms that may require months or years to become fully clinically manifest. Conversely, the use of neuroimaging techniques can significantly shorten the diagnostic process and prove a useful means to the neurologist in those cases presenting with uncertain clinical diagnosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15033144     DOI: 10.1016/j.sleep.2003.10.013

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  6 in total

Review 1.  Positron emission tomography for benign and malignant disease.

Authors:  Anthony Visioni; Julian Kim
Journal:  Surg Clin North Am       Date:  2011-02       Impact factor: 2.741

Review 2.  The Place of PET to Assess New Therapeutic Effectiveness in Neurodegenerative Diseases.

Authors:  Anne-Claire Dupont; Bérenger Largeau; Denis Guilloteau; Maria Joao Santiago Ribeiro; Nicolas Arlicot
Journal:  Contrast Media Mol Imaging       Date:  2018-05-17       Impact factor: 3.161

Review 3.  Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments.

Authors:  Panchanan Maiti; Jayeeta Manna; Gary L Dunbar
Journal:  Transl Neurodegener       Date:  2017-10-25       Impact factor: 8.014

4.  Reduced Gray Matter Volume and Risk of Falls in Parkinson's Disease with Dementia Patients: A Voxel-Based Morphometry Study.

Authors:  Kai-Lun Cheng; Li-Han Lin; Po-Cheng Chen; Pi-Ling Chiang; Yueh-Sheng Chen; Hsiu-Ling Chen; Meng-Hsiang Chen; Kun-Hsien Chou; Shau-Hsuan Li; Cheng-Hsien Lu; Wei-Che Lin
Journal:  Int J Environ Res Public Health       Date:  2020-07-26       Impact factor: 3.390

5.  The role of I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies.

Authors:  Angelo Antonini
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

6.  CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson's disease.

Authors:  Nora Bengoa-Vergniory; Emilie Faggiani; Paula Ramos-Gonzalez; Ecem Kirkiz; Natalie Connor-Robson; Liam V Brown; Ibrar Siddique; Zizheng Li; Siv Vingill; Milena Cioroch; Fabio Cavaliere; Sarah Threlfell; Bradley Roberts; Thomas Schrader; Frank-Gerrit Klärner; Stephanie Cragg; Benjamin Dehay; Gal Bitan; Carlos Matute; Erwan Bezard; Richard Wade-Martins
Journal:  Nat Commun       Date:  2020-09-28       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.